Allografting Older Patients—Myths and Realities  by Giralt, Sergio
From the
Thera
Cente
Financial d
Correspon
Stem
of Te
77030
1083-8791
doi:10.101
146Allografting Older Patients—Myths and Realities
Sergio GiraltINTRODUCTION
Other vulnerable populations that need special
consideration include older age patients. Because of
toxicity and nonrelapse mortality (NRM), allografting
with conventional myeloablative conditioning is rarely
performed in patients older than 50 years of age, and
autografting in patients over the age of 65 years is per-
formed in only a few centers. Both single-institution
and registry analyses show that older age is associated
with a higher incidence of graft-versus-host disease
(GVHD) and NRM [1-3]. The biologic basis underly-
ing the increased incidence ofNRM in older patients is
not well understood, although most studies show
a relationship of acute GVHD (aGVHD) with age [4].
Improvements in supportive care and the use of
peripheral blood stem cells (PBSC), together with im-
proved HLA typing technology, have improved trans-
plant outcomes in younger patients [5]. Although some
centers have shown that conventional allografting can
be successful in patients over the age of 55 years, the
number of patients over 55 years who had until recently
undergone allografting was extremely small [6,7]. The
change in age distribution of transplant recipients over
the last 20 years is summarized in Figure 1A and B.
Transplanting older patients has unique chal-
lenges; not only are comorbidities more common,
but in some instances the risk-benefit ratios favor
a more conservative approach when compared to
younger patients with the same disease. What is sur-
prising, however, is the number of instances in which
aggressive therapy is actually indicated and appropri-
ate for older patients. In this section, we will review
some of the current studies regarding stem cell trans-
plant (SCT) in older patients. In the last section we
will discuss the comorbidity index and its applicability
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Conditioning (RIC) Regimens for Older Patients
with Acute Myelogenous Leukemia (AML)
The potency of the immune-mediated graft-
versus-leukemia (GVL) effect as demonstrated by the
ability of donor lymphocyte infusions (DLIs) to rein-
duce remissions in patients who have relapsed after
an allogeneic progenitor cell transplant has led to the
exploration of RIC regimens in older and medically
debilitated patients [8-12]. Since the advent of RIC,
the fraction of patients over the age of 55 years who
are undergoing allogeneic transplantation has in-
creased significantly and represents 1 of the largest
areas of growth for this procedure, as can be seen in
Table 1. Notwithstanding, most allografted patients
are still \70 years of age, with only 54 patients re-
ported to the registry .70 years of age [13]. Kiss et
al. [14] recently reviewed the results of allografting
for older patients with AML undergoing RIC allog-
rafting. In general, 2- to 3-year NRM rates between
10% and 30% are reported with 3-year event-free sur-
vival (EFS) rates between 30% and 50% for patients
undergoing RIC allografting for AML/myelodysplas-
tic syndromes (MDS) in remission [15-22]. Unfortu-
nately, as demonstrated by Estey et al. [22], only
a minority of patients achieving a complete remission
actually undergo this procedure. There is a significant
difference in dose intensity among the different RIC
and minimally ablative regimens that are currently
used [14]. Although dose intensity has been reported
to be important for disease control after allografting
in AML/MDS [16], none of the retrospective studies
have demonstrated a benefit of 1 conditioning over
another.Timing of SCT in the Elderly AML/MDS Patients
Considering that the outcome for elderly patients
with AML/MDS is so poor, one would think that
most patients should be transplanted as soon as the di-
agnosis is made. The logistics of finding a donor, plus
the poor performance status of many elderly patients
with AML/MDS makes this difficult. Even in patients
achieving a complete remission, the number of pa-
tients undergoing allografting is \15% [22]. The
emerging data regarding the safety and efficacy of
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Figure 1. (A) Trends in allogeneic bone marrow transplant (1984-2002). (B) Trends in autologous transplantation (1990-2002).
Biol Blood Marrow Transplant 15:146-148, 2009 147Vulnerable Transplant Patientsthis procedure should allow more patients and physi-
cians to consider this as a valid option. However, pa-
tients with high comorbidity scores (see next section)
and poor performance status continue to have a high
rate of treatment-related complications and mortality
(TRM) rates of 40% at 3 years, and the risk benefit ra-
tio needs to be addressed with patients and family
members before embarking on this procedure [23].
The lack of a related sibling donor or a suitable 10/
10 unrelated donor also should not be considered an
absolute barrier to proceed to allografting in elderly
AML/MDS patients, because recent reports from the
University of Minnesota have shown the feasibility
and efficacy of unrelated donor cord blood transplan-
tation using RIC regimens in older patients; however,
this approach should still be limited to well-designed
clinical trials [24].
Older patients with other hematologic malignan-
cies have also been treated with allogeneic SCT. These
series include a variety of both acute and chronic
lymphogenous and myelogenous malignancies, and
firm conclusions regarding the role of allografting in
older patients with these disorders cannot be made.
Notwithstanding, the preliminary analysis in patients
with low-grade non-Hodgkin lymphoma (NHL) and
chronic lymphocytic leukemia (CLL) are encouraging.CONCLUSION
The development of RIC regimens has allowed
physicians and patients to explore the option of long-
term disease control. The risk-benefit ratio for this
procedure will depend on the disease state, and the
performance status of the patient. Better risk stratifica-
tion through the use of the cormorbidity index, which
is discussed below, may also help in patient assessment
and the choice of conditioning regimens. Current re-
sults underscore that age by itself should no longer
be a contraindication for allogeneic transplant with cu-rative intent in these patients, and long-term disease
control with good quality of life is possible and can
be expected. Future trials combining novel therapies
as well as novel transplant technologies should allow
more elderly patients with AML or MDS to achieve
long and productive lives.ACKNOWLEDGMENTS
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